Cover image of the article: Long-term survival in a patient with chronic myelogenous leukemia without  any treatment

Image Credit:J Kermanshah Univ Med Sci

Long-term survival in a patient with chronic myelogenous leukemia without any treatment

Authors

A Shahriari1,*, HR Emaami1
1Iran
*Corresponding Author: Corresponding author: A Shahriari, Iran, E-mail: Email: journal@kums.ac.ir

Journal of Kermanshah University of Medical Sciences:Vol. 6, issue 2; e81011
Published online:Sep 19, 2002
Article type:Case Report
Received:Apr 11, 2002
Accepted:Sep 11, 2002
How to Cite: Shahriari A, Emaami H. Long-term survival in a patient with chronic myelogenous leukemia without any treatment. J Kermanshah Univ Med Sci. 2002;6(2):e81011. doi:

Abstract

Chronic myelogenous leukemia (CML) is a myeloproliferative disease with a well known course. With chemotherapy,   average survival of these  patients is   3-5 years. All of the   long term survivors  of CML   have been  treated patients. Here we are reporting on a  long term survivor (more than 10 years)  without treatment.

Highlights

Fulltext

The full text of this article is available on PDF

Copyright

© 2002, Journal of Kermanshah University of Medical Sciences. This open-access article is available under the Creative Commons Attribution-NonCommercial 4.0 (CC BY-NC 4.0) International License (https://creativecommons.org/licenses/by-nc/4.0/), which allows for the copying and redistribution of the material only for noncommercial purposes, provided that the original work is properly cited.

Similar Articles

30
Apr
2015
Appearance of Acute Myelogenous Leukemia (AML) in a Patient with Breast Cancer after Adjuvant Chemotherapy: Case Report and Review of the Literature

Appearance of Acute Myelogenous Leukemia (AML) in a Patient with Breast Cancer after Adjuvant Chemotherapy: Case Report and Review of the Literature

Mehrdad Payandeh,
Reza Khodarahmi,
Masoud Sadeghi,
Edris Sadeghi

Payandeh M, Khodarahmi R, Sadeghi M, Sadeghi E. Appearance of Acute Myelogenous Leukemia (AML) in a Patient with Breast Cancer after Adjuvant Chemotherapy: Case Report and Review of the Literature. Int J Cancer Manag. 2015;8(2):e80601. doi:

22
Feb
2016
New Developments in Chronic Myeloid Leukemia: Implications for Therapy

New Developments in Chronic Myeloid Leukemia: Implications for Therapy

Sanaz Tabarestani,
Abolfazl Movafagh

Tabarestani S, Movafagh A. New Developments in Chronic Myeloid Leukemia: Implications for Therapy. Int J Cancer Manag. 2016;9(1):e3961. doi: https://doi.org/10.17795/ijcp-3961

20
Feb
2012
Five-year survival rate of pediatric leukemia and its determinants

Five-year survival rate of pediatric leukemia and its determinants

Sohila Zareifar,
Amir Almasi-Hashiani,
Mehran Karimi,
hamidreza tabatabaee,
Reza Ghiasvand

Zareifar S, Almasi-Hashiani A, Karimi M, tabatabaee H, Ghiasvand R. Five-year survival rate of pediatric leukemia and its determinants. koomesh. 2012;14(1):e153844. doi:

25
Nov
2012
Survival Rate of Childhood Leukemia in Shiraz, Southern Iran

Survival Rate of Childhood Leukemia in Shiraz, Southern Iran

Amir Almasi-Hashiani,
Soheil Zareifar,
Mehran Karimi,
Esmaeil Khedmati,
Abolfazl Mohammadbeigi

Almasi-Hashiani A, Zareifar S, Karimi M, Khedmati E, Mohammadbeigi A. Survival Rate of Childhood Leukemia in Shiraz, Southern Iran. Inn J Pediatr. 2013;23(1):. doi:

30
Apr
2015
Cholorambucil versus Cholorambucil Plus Prednisolone as First-Line Therapy of Chronic Lymphocytic Leukemia in West of Iran

Cholorambucil versus Cholorambucil Plus Prednisolone as First-Line Therapy of Chronic Lymphocytic Leukemia in West of Iran

Mehrdad Payandeh,
Masoud Sadeghi,
Edris Sadeghi

Payandeh M, Sadeghi M, Sadeghi E. Cholorambucil versus Cholorambucil Plus Prednisolone as First-Line Therapy of Chronic Lymphocytic Leukemia in West of Iran. Int J Cancer Manag. 2015;8(2):e80597. doi:

More by these authors

A ShahriariPubMedScholar
HR EmaamiPubMedScholar
Share
Cited by
Metrics